Amgen Pays $200M To Settle Antitrust Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
No wrongdoing admitted in case filed by Ortho Biotech over anemia drugs.
You may also be interested in...
Aranesp Contracts Revised: 50% Share Of ESA Purchases Qualifies Clinics For Best Discount
Amgen will restructure its previously bundled oncology portfolio contract for Aranesp, Neulasta and Neupogen into separate product contracts.
Aranesp Contracts Revised: 50% Share Of ESA Purchases Qualifies Clinics For Best Discount
Amgen will restructure its previously bundled oncology portfolio contract for Aranesp, Neulasta and Neupogen into separate product contracts.
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call